This research is studying a vaccine against Mpox (formerly known as monkeypox) that is FDA approved for adults but not yet approved for children. The goal of the study is to determine if the vaccine protects children just as well as it protects adults. The study is also looking at the safety of the vaccine. This study is open to healthy adolescents, ages 12-17. In addition, adolescents with certain immunodeficiency diseases or other conditions, that are well controlled, are eligible to participate. 

This study will measure components or metabolites of PEG 3350 in blood and urine from children who are already taking PEG 3350 and compare these levels to measurements of the same molecules from a group of children who are not taking PEG 3350. PEG 3350 will not be prescribed as part of this study. Participants will complete questionnaires and provide access to their medical records. The study is being conducted in collaboration with Ohio State University and the US Food and Drug Administration.

The purposes of this study is to examine efficacy of the IDEAL2 (Improving Diet and Exercise in ALL) caloric restriction and activity intervention integrated into HR B-ALL induction to reduce incidence of end of induction (EOI) MRD ≥0.01%.

The goal of this research study is to compare sex and gender development differences between children ages 4-8 years who are on the autism spectrum with children who are not on the autism spectrum. 

The purpose of this study is to collect and store data samples, such as stool samples, mouth swabs and saliva specimens for research about the microbiome. The microbiome is a collection of the microbes, or very small forms of life, that live on and inside the human body.

CAR T cell therapy has shifted the treatment landscape for pediatric and young adult patients with advanced B-cell leukemias. However, the manufacturing process remains in its first generation: difficult, time-consuming, and not automated. The time and significant resources in this process can result in patient safety issues - with patients growing sicker, with harder to control leukemias - in the waiting period. Use of the CliniMACS Prodigy platform can help to surmount these issues. This study will determine the safety and usefulness of using the CliniMACS Prodigy platform to manufacture huCART19 cells.

This is a Phase 1/2b trial for the treatment of patients with either advanced or refractory B cell Acute Lymphoblastic Leukemia or B-lineage lymphoblastic lymphoma who will be treated with huCART19, which has been manufactured using the CliniMACs Prodigy Platform. Possible procedures include medical record review, apheresis, huCART19 infusion, blood draws, physical exams, imaging, and disease assessments through bone marrows and lumbar punctures. Overall, approximately 89 subjects will be enrolled on this clinical trial.

The purpose of this research study is to test and adapt new techniques for performing magnetic resonance imaging (MRI). MRI provides pictures of the inside of the body and information about chemicals the body makes. Here are some examples of what we hope to accomplish:

1. Adapt MRI techniques used at other institutions for use on CHOP MRI scanners

2. Increase the amount of information learned from each MRI image

The research sequences involve changing the settings of the magnetic resonance scanner. By research sequences we mean that they are not approved by the US Food and Drug Administration (FDA) for clinical use. The data we obtain will help the FDA evaluate whether or not they can eventually approve the sequences for clinical use.

We are seeking to enroll healthy volunteers, 18 years of age and above. Pregnant females excluded for safety purposes.

The purpose of this study is to identify and engage young black or hispanic/latino men (male sex at birth, but gender identity male, transfemale, or gender nonconforming) (YBLMSM/transwomen) in Philadelphia, PA, Baltimore, MD and Washington, DC in HIV and substance use prevention using a new Mobile-enhanced Engagement intervention (app that reminds you to take your meds, reminds you of your medical appointments, etc.). There are three different parts to this study: 1) respondent driven sampling (RDS); 2) Randomized Control Trial (RCT): MEI vs Standard of Care for HIV+ youth; and 3) PrEP RCT: Pre Exposure Prophylaxis - Mobile-enhanced Engagement Intervention (PrEP-MEI) vs. Standard PrEP referral;. It is possible to participate in only the RDS, the RDS and the AIM 3 PrEP RCT, or the RDS and AIM 2 RCT studies.

The RDS study involves 2 study visits lasting up to 1 month of participation where participants will be asked to complete an optional rapid HIV test (oral or fingerstick) or viral load testing (blood draw), web-based survey (on past sexual and HIV experiences), recruit your peers to participate in the study, and complete a post-recruitment survey. YBLMSM/transwomen and cisgender females 15-24 years may participate in RDS, but the following study portions are only for YBLMSM/transwomen:

People who successfully complete the RDS portion of the study may be asked to participate in an additional study visit of an audio-recorded focus group or interview.

The RCT study involves 6 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different HIV supportive interventions: 1) HIV case management with a Mobile-enhanced Engagement Intervention (MEI), or 2) standard of care HIV case management where a case manager will remind you of medical appointments. If you are assigned to the first group (MEI), you will be asked to use the MEI mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody and Viral load testing (blood draw), urine drug testing, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.

The PrEP RCT study involves 5 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different PrEP and substance use supportive interventions: 1) PrEP case management with a Mobile-enhanced Engagement Intervention (MEI-PrEP), or 2) standard PrEP referrals to services. If you are assigned to the first group (MEI-PrEP), you will be asked to use the MEI-PrEP mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody (blood draw or 2 rapid OraQuick tests in place of serologic 4th generation testing when 4th generation testing is not available) and Viral load testing (blood draw), urine drug testing, use the MEI-PrEP mobile app or web-browser version of the app, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.

We are currently enrolling adolescents ages 15-21 of South Asian ancestry, African American ancestry, and European American or "White" ancestry. This study is looking to better understand ancestry related differences in risks for developing cardiovascular disease and type 2 diabetes. The study involves 2 visits to the CHOP Main Hospital in Philadelphia, and participants will be compensated for their efforts.